OncoDaily IO shared a post on LinkedIn:
“New Paper Alert – JAMA Network Open.
Real-world data confirms: Perioperative chemoimmunotherapy significantly improves 18-month distant metastasis-free survival (DMFS) in resectable stage II-IIIA NSCLC.
Yet in 2023, <30% of eligible patients received it.
Key Study Highlights:
- N = 1,334 | Flatiron Health EHR database
- DMFS:
- Neoadjuvant: 80.2%
- Adjuvant: 83.0%
- DMFS ≥95% when ≥12 months of adjuvant immunotherapy is completed
Challenges Identified:
- Underutilization in real-world settings
- Suboptimal biomarker testing (<60% in neoadjuvant cohort)
- Variability in treatment duration
Urgent need for:
- Improved biomarker testing workflows
- Greater multidisciplinary uptake
Read the full study: Desai et al, JAMA Network Open, June 2025.
Summary.“
